Human Herpesvirus 3

For the assessment of cell-mediated immunity using Human Herpesvirus 3 extracts, the standard adult dosage is typically 0.1 mL of the prepared extract. This is administered via the intradermal (Mantoux) method. Healthcare providers generally use a 26- or 27-gauge needle and a tuberculin syringe to ensure precise delivery. The injection is usually placed on the volar surface (inner side) of the forearm, approximately 2 to 4 inches below the elbow.

If multiple antigens are being tested simultaneously (an anergy panel), each injection site should be separated by at least 2 to 5 cm to prevent the overlapping of inflammatory responses, which could lead to inaccurate readings.

Human Herpesvirus 3 skin testing is generally approved for pediatric use; however, the clinical necessity must be established by a pediatric immunologist or allergist. The dosage remains 0.1 mL administered intradermally. In infants and small children, the skin is thinner, and extreme care must be taken to ensure the injection is truly intradermal and not subcutaneous, as a subcutaneous injection may result in a false-negative response or increased local irritation.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the systemic absorption of the HHV-3 extract is negligible.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment. The localized nature of the diagnostic test does not tax the liver's metabolic capacity.

Elderly Patients

Elderly patients may exhibit reduced skin reactivity due to the natural senescence of the immune system (immunosenescence). While the dose remains 0.1 mL, healthcare providers must interpret results cautiously, as a negative result in an older adult may reflect age-related immune decline rather than a specific pathological immunodeficiency.

Human Herpesvirus 3 extracts are never self-administered by the patient. They must be administered by a qualified healthcare professional in a clinical setting equipped to handle potential allergic reactions.

• Preparation: The skin site should be cleaned with an alcohol swab and allowed to air dry.
• Technique: The needle is inserted bevel-up at a 5- to 15-degree angle. A successful intradermal injection will produce a distinct pale 'wheal' or bleb (a small bump) approximately 6 to 10 mm in diameter.
• Observation: The patient should remain in the clinic for at least 15 to 30 minutes following the injection to monitor for immediate hypersensitivity or anaphylactic reactions.
• Reading: The test must be 'read' by a healthcare professional 48 to 72 hours after the injection. The professional will measure the diameter of the induration (the hard, raised area) in millimeters. Erythema (redness) alone is not considered a positive result.
• Storage: Vials should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They must not be frozen.

Since this is a diagnostic test and not a therapeutic regimen, a 'missed dose' refers to a missed reading appointment. If you do not have the test site read within the 48- to 72-hour window, the results may be invalid. In such cases, the test usually needs to be repeated on the opposite arm or at a later date as determined by your doctor.

An overdose of Human Herpesvirus 3 extract in a diagnostic setting is highly unlikely but could occur if a systemic dose is accidentally administered or if multiple sites are injected with excessive volume.

• Signs: Severe local inflammation, blistering, or necrosis (tissue death) at the injection site. Systemic signs could include fever, malaise, or a widespread rash.
• Emergency Measures: If a systemic reaction occurs, emergency supportive care, including the administration of epinephrine, antihistamines, or corticosteroids, may be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to interpret the skin test results without medical guidance.

Most patients receiving a Human Herpesvirus 3 skin test will experience some level of localized reaction, which is often the intended diagnostic outcome. Common side effects include:

• Local Erythema: Redness at the injection site is very common. This typically appears within hours and may persist for several days. It is often described as a warm, itchy, or slightly tender area.
• Induration: A firm, raised bump at the site. While this is the goal of the test, it can be uncomfortable or itchy. In highly sensitive individuals, the induration may exceed 20 mm in diameter.
• Pruritus (Itching): Intense itching at the injection site is frequent as the immune system reacts to the viral proteins. Patients are advised not to scratch the area, as this can cause skin breakdown or infection.

• Local Pain and Tenderness: Some patients may experience significant discomfort at the injection site, making it difficult to wear tight clothing over the arm.
• Ecchymosis (Bruising): Minor bruising may occur if a small blood vessel is nicked during the intradermal injection.
• Lymphadenopathy: Swelling of the lymph nodes in the axilla (armpit) of the arm used for the test may occur as the immune system processes the antigen.

• Vesiculation and Ulceration: In individuals with extreme sensitivity to HHV-3, the test site may develop blisters (vesicles) or even a small open sore (ulcer). This usually heals without scarring but requires keeping the area clean.
• Arthus Reaction: A localized Type III hypersensitivity reaction characterized by severe inflammation, edema, and sometimes localized tissue necrosis due to the formation of antigen-antibody complexes.
• Syncope (Fainting): Some patients may experience a vasovagal response (fainting) due to the needle stick rather than the extract itself.

While extremely rare with diagnostic extracts, systemic allergic reactions can occur.

> Warning: Stop taking Human Herpesvirus 3 and call your doctor immediately if you experience any of these:

• Anaphylaxis: A life-threatening allergic reaction characterized by difficulty breathing, swelling of the face or throat, rapid heartbeat, and a sharp drop in blood pressure.
• Generalized Urticaria: Hives that spread across the entire body, not just at the injection site.
• Angioedema: Deep swelling under the skin, particularly around the eyes, lips, or tongue.
• Shortness of Breath or Wheezing: Indicative of bronchospasm or airway constriction.

Because Human Herpesvirus 3 extracts are used for one-time or infrequent diagnostic testing, long-term side effects are virtually non-existent. There is no evidence that the small amount of inactivated or processed viral antigen used in skin testing leads to chronic health issues or the development of shingles. The primary long-term consideration is the potential for 'boosting,' where the skin test itself slightly increases the body's immune memory of the virus, potentially affecting the results of future tests.

There are currently no FDA black box warnings specifically for Human Herpesvirus 3 non-standardized extracts. However, general warnings for all allergenic extracts emphasize that they should only be administered by clinicians prepared to manage severe anaphylaxis. The risk of systemic reactions is significantly higher when extracts are used for immunotherapy (allergy shots) compared to the diagnostic skin testing described here.

Report any unusual symptoms, especially those that persist beyond 72 hours, to your healthcare provider.

Human Herpesvirus 3 extracts are diagnostic tools and must be handled with the same caution as any biological product. The most critical safety point is that this extract is for intradermal use only. It must never be injected intravenously, as this could trigger a severe systemic inflammatory response. Furthermore, the test results provide information about the patient's immune status but do not diagnose an active chickenpox or shingles infection.

No FDA black box warnings for Human Herpesvirus 3 extracts are currently issued. However, the general class warning for allergenic extracts states that they may cause severe life-threatening systemic reactions, including anaphylaxis. These products should only be used in settings where emergency resuscitative equipment and personnel are available.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known history of severe allergy to any components of the extract (such as phenol or glycerin) should not undergo testing. A history of severe reaction to the Varicella vaccine may also be a contraindication.
• Risk of False Negatives: Patients who are severely immunocompromised may not react to the skin test even if they have been previously exposed to HHV-3. This is known as anergy. Healthcare providers must not use a negative skin test as definitive proof that a patient has never had HHV-3.
• Acute Infection: Testing should be postponed in patients suffering from acute viral or bacterial infections, as the body's immune resources are diverted, potentially leading to suppressed DTH responses.
• Skin Conditions: The test should not be performed on skin areas with active dermatitis, psoriasis, or extensive scarring, as these conditions interfere with the ability to accurately read the induration.

No long-term lab tests are required for this diagnostic procedure. However, the following monitoring is standard:

• Immediate Observation: Monitoring for 30 minutes post-injection for signs of anaphylaxis.
• Site Monitoring: The patient should be instructed to monitor the site for excessive swelling, red streaks (lymphangitis), or pus, which could indicate a secondary bacterial infection.

Human Herpesvirus 3 extracts generally do not affect the ability to drive or operate machinery. However, if a patient experiences a vasovagal reaction (dizziness or fainting) during the procedure, they should wait until they feel fully recovered before leaving the clinic.

There are no known direct interactions between alcohol and the HHV-3 extract. However, excessive alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the redness at the test site, potentially complicating the reading of the result.

As this is a single-use diagnostic test, there is no discontinuation or tapering process. Once the test is read at 72 hours, no further action is required unless a local complication occurs.

> Important: Discuss all your medical conditions, especially any history of fainting or severe allergies, with your healthcare provider before starting Human Herpesvirus 3 testing.

There are no absolute drug-drug contraindications that make the use of Human Herpesvirus 3 extract dangerous; however, certain medications will render the test clinically useless by suppressing the immune response:

• High-Dose Systemic Corticosteroids: Drugs like prednisone (usually doses >20mg/day) or dexamethasone significantly inhibit T-cell function and cytokine release. This will lead to a false-negative result. Testing should typically be delayed until the patient has been off steroids for at least two weeks.

• Immunosuppressants and Biologics: Medications used for transplant rejection (cyclosporine, tacrolimus) or autoimmune diseases (TNF-inhibitors like adalimumab or etanercept) suppress the very pathways the HHV-3 skin test measures. If a patient is on these drugs, a negative skin test result cannot be used to confirm a lack of immunity.
• Chemotherapy: Cytotoxic agents that deplete white blood cell counts will naturally suppress the DTH response. Testing should be timed according to the patient's oncology schedule.

• Cimetidine: Some studies suggest that H2-blockers like cimetidine might actually enhance DTH responses by inhibiting suppressor T-cells. This could theoretically lead to an exaggerated local reaction.
• Topical Corticosteroids: If applied directly to the test site, topical steroids (like hydrocortisone cream) will suppress the local inflammatory response and invalidate the reading.

There are no known interactions between Human Herpesvirus 3 extracts and specific foods. Patients do not need to fast or alter their diet before the skin test.

• Echinacea and Astragalus: These herbs are often taken to 'boost' the immune system. While there is no definitive clinical data, they could theoretically cause a more robust local reaction to the HHV-3 antigen.
• St. John's Wort: While primarily known for its interaction with CYP450 enzymes, it does not typically interfere with the localized T-cell mediated response of a skin test.

• Tuberculin (PPD) Skin Test: If a patient is undergoing both a TB skin test and an HHV-3 skin test, they should ideally be performed on different arms. There is a theoretical risk that the immune response to one antigen could slightly modulate the response to the other.
• Viral Vaccines: Live virus vaccines (such as MMR or Varicella vaccine) can cause a temporary suppression of T-cell skin reactivity. It is generally recommended to perform skin testing either on the same day as vaccination or wait 4-6 weeks after vaccination to avoid false-negative results.

For each major interaction, the mechanism involves the modulation of the cytokine cascade or the direct suppression of lymphocyte proliferation. The clinical consequence is almost always a reduction in the accuracy of the diagnostic test. The management strategy is typically to wait for the medication to clear the system or to interpret the results with extreme caution.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your immune system.

Human Herpesvirus 3 extracts must NEVER be used in the following circumstances:

• Known Hypersensitivity to Extract Components: If a patient has a documented severe allergy to phenol (the preservative) or any other inactive ingredient in the solution, the test is strictly contraindicated. The risk of anaphylaxis outweighs any diagnostic benefit.
• History of Severe Reaction to HHV-3 Testing: Patients who have previously experienced an Arthus reaction or extensive tissue necrosis from a previous HHV-3 skin test should not be re-tested.
• Active Varicella or Zoster Infection: Testing a patient who currently has chickenpox or shingles is unnecessary and could potentially exacerbate the patient's discomfort or systemic inflammatory state.

Conditions requiring a careful risk-benefit analysis include:

• Pregnancy: While the extract is not a live virus and systemic absorption is minimal, the stress of an inflammatory reaction or a potential allergic response must be weighed against the need for the diagnostic information.
• Severe Dermatitis: If the skin is not intact or is heavily inflamed, the test results cannot be accurately interpreted.
• Bleeding Disorders: Patients with hemophilia or those on high-dose anticoagulants (like warfarin) may experience significant bleeding or hematoma formation at the injection site.

Patients who are allergic to other members of the Herpesviridae family (such as Herpes Simplex Virus 1 or 2) may theoretically show increased sensitivity to the HHV-3 extract due to shared viral proteins, though this is rarely a contraindication for diagnostic use. More importantly, cross-sensitivity to the Varicella-Zoster vaccine components (like gelatin or neomycin, if present in the extract) must be considered.

> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing Human Herpesvirus 3 skin testing.

Human Herpesvirus 3 extracts are generally classified under FDA Pregnancy Category C. This means that adequate and well-controlled studies in pregnant women are lacking. Because the extract is used for diagnostic purposes and involves only a tiny amount of processed antigen, it is unlikely to pose a direct risk to the fetus. However, maternal anaphylaxis, though rare, could be catastrophic for the pregnancy. Therefore, skin testing should only be performed during pregnancy if the information is vital for the management of the mother's health and cannot be obtained through blood tests (serology).

It is not known whether components of the HHV-3 extract are excreted in human milk. However, given the intradermal route of administration and the minimal systemic bioavailability, the concentration in breast milk is expected to be negligible. There is no known risk to the nursing infant. Healthcare providers generally consider diagnostic skin testing to be compatible with breastfeeding.

Human Herpesvirus 3 skin testing is safe for use in children when performed by experienced clinicians. It is primarily used in the pediatric population to investigate suspected primary immunodeficiencies (e.g., DiGeorge Syndrome). It is important to note that children under the age of one may not have had enough exposure to HHV-3 (either through vaccination or natural infection) to mount a DTH response, leading to a high rate of false negatives in this age group.

In patients over the age of 65, the 'waning' of cell-mediated immunity is a common phenomenon. This can lead to smaller induration sizes or completely negative results despite a history of chickenpox. Geriatric patients are also more likely to be taking multiple medications (polypharmacy) that could interfere with the test results. Clinicians should use HHV-3 testing in the elderly primarily to assess the general state of the immune system rather than to confirm specific VZV immunity.

Patients with chronic kidney disease (CKD), especially those on dialysis, often exhibit 'uremic anergy.' This is a state where the body's T-cells do not respond normally to antigens. In these populations, a negative HHV-3 skin test is common and should be interpreted as a sign of the patient's overall suppressed immune state rather than a specific lack of HHV-3 memory.

Hepatic impairment does not significantly alter the pharmacokinetics of the HHV-3 extract. However, patients with advanced cirrhosis may have associated immune dysfunction that can lead to reduced skin test reactivity.

> Important: Special populations require individualized medical assessment to ensure that the diagnostic test is both safe and interpretable.

Human Herpesvirus 3 extract acts as a diagnostic probe for the Type IV hypersensitivity arm of the immune system. Unlike vaccines, which aim to induce new immunity, this extract is designed to detect existing memory T-cell responses. The molecular mechanism involves the processing of VZV glycoproteins (such as gE, gB, and gH) by dermal dendritic cells. These cells then present the viral peptides to memory CD4+ T-lymphocytes. If the patient has been previously sensitized, these T-cells secrete pro-inflammatory cytokines like IFN-γ, which activate local vascular endothelium and recruit macrophages. This cellular influx creates the palpable induration that is measured by the clinician.

The dose-response relationship for HHV-3 extract is non-linear; once the threshold for T-cell activation is met, the size of the reaction is more dependent on the patient's 'immune vigor' than the exact amount of antigen. The time to onset of the visible reaction is typically 12-24 hours, with the peak effect (maximal induration) occurring at 48-72 hours. The duration of the effect is self-limiting, with most reactions resolving within 7 to 10 days as the inflammatory cells disperse.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Systemic) |

| Protein Binding | N/A (Localized) |

| Half-life | ~24-48 hours (at injection site) |

| Tmax | 48-72 hours (for induration) |

| Metabolism | Local Proteolysis |

| Excretion | Lymphatic Clearance |

The extract is a complex biological mixture containing proteins, glycoproteins, and lipids derived from the Human Herpesvirus 3 (Varicella-Zoster Virus). The virus is typically grown in human diploid cell cultures (such as MRC-5 cells), then harvested and inactivated. The molecular weight of the active glycoproteins ranges from 50 to 100 kDa. The solution is usually clear, with a pH adjusted to 6.5-7.5 for physiological compatibility.

Human Herpesvirus 3 is classified as a Non-Standardized Allergenic Extract. It belongs to the broader category of diagnostic biologicals. Within this class, it is grouped with other DTH antigens like Tuberculin PPD, Candida albicans extract, and Mumps skin test antigen. These agents are the gold standard for in-vivo assessment of cell-mediated immunity.